Javelin Pharmaceuticals Inc (JAV)

[Bio_pete]

The platelet study was the difference in Dyloject being a $250 million + drug in the US vs $100 million. There is no reason to use the primary NSAID (ketorolac)for post-operative pain once Dyloject is approved.

Ketorolac had over 43 million unit doses sold in the US in 2006 eventhough it has a black box warning. Once JAV does a little marketing then it will become the standard.

I don't see any reason why JAV couldn't do 50 million units within 2 yrs of approval since the trend in post-operative pain management promotes the increased use of NSAIDs. 50 million X $7 dose = $350 million.